Despite extensive experimental studies investigating underlying mechanisms, advancement of novel therapeutic strategies to specifically target CHF are limited, with long-standing pharmacological treatments, such as ACE inhibitors and β-blockers, remaining as the standard approach to clinical management. The gene discussed is ACE; the disease is congestive heart failure.